FoRx discloses structure of PARG inhibitor candidate FORX-428
The clinical-stage compound was first presented at the ACS Spring 2026 meeting, with Phase 1 trial readouts expected by the end of 2026.
See the latest news and media coverage for FoRx. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage biotechnology company developing targeted cancer therapeutics
forxtherapeutics.comLast updated
In short: FoRx disclosed FORX-428’s structure and said Phase 1 readouts were expected by the end of 2026.
The clinical-stage compound was first presented at the ACS Spring 2026 meeting, with Phase 1 trial readouts expected by the end of 2026.
The data confirm the PARG inhibitor's best-in-class potential, revealing its novel molecular structure and superior potency against PARP inhibitor-resistant tumors. Initial Phase 1 data are expected mid-2026.
Existing investors including EQT Life Sciences, Pfizer Ventures, Novartis Venture Fund and M Ventures participate. The funds advance Phase 1 development of PARG inhibitor FORX-428, with initial data expected mid-2026.
The open-label Phase 1 study in advanced solid tumors starts in the U.S., with initial data expected by mid-2026.
FORX-428 is potential new treatment option for patients whose cancers are resistant to, or have become resistant to, PARP inhibitors Initial data expected in mid-2026...
Funding to support Phase 1 clinical development of best-in-class PARG inhibitor candidate FORX-428 FORX-428 is potential new treatment option for patients whose cancers are resistant...
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. Funding...
Basel, Switzerland - August 11, 2025 - FoRx Therapeutics, a clinical-stage biotechnology company developing precision anti-cancer therapeutics, today announced the dosing of the first patient...
Track FoRx and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to FoRx and other trending companies.